A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer
Lee Steven Schwartzberg, Francis P. Arena, Bryan J. Bienvenu et al. · Journal of Cancer · 2017
Background: This study was designed to assess the safety and preliminary efficacy of KLTi plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.Methods: In a randomized, open-label study, patients with locally advanced or metastatic pancreatic cancer were randomized 2:1 to receive KLTi plus gemcitabine or gemcitabine monotherapy.Three sequential cohorts were tested at 30 g/day, 50 g/day, and 30 g/day.Gemcitabine was administered at 1000 mg/m 2 on days 1, 8 and 15 of each 28 day cycle.KLTi was administered on days 1-5, 8-12, and 15-19 of each 28 day cycle.Patients received study treatment until disease progression.The primary endpoint was progression-free survival in the ITT population.Safety evaluation was based on patients who received any study treatment.ClinicalTrials.govidentifier NCT00733850.Results: Eighty-five patients were randomized including 41 (28:13) in Cohort 1, 18 (12:6) in Cohort 2, and 26 (17:9) in Cohort 3. Due to a different dose and/or shift in patient populations in Cohort 2 and 3, efficacy data for the 30 gm dose are presented in this manuscript for Cohort 1 alone, and for the combination of Cohort 1+3.The 30 gm KLTi + gemcitabine group had a statistically significant improvement in progression-free survival (PFS) as assessed by blinded independent radiology review in the ITT population, with a median of 112 days, versus 58 days in the gemcitabine group (HR 0.50; 95% CI: 0.27, 0.92), p = 0.0240.The incidence rates of TEAEs, CTCAE Grade 3 or higher TEAEs, and SAEs were similar between the two arms.There were no deaths related to KLTi + gemcitabine treatment.Conclusion: Kanglaite Injection (30 g/day) plus a standard regimen of gemcitabine demonstrated encouraging clinical evidence of anti-neoplastic activity and a well-tolerated safety profile.
Cited by 49 works. doi:10.7150/jca.15407 Open-access PDF
Authors
- Lee Steven Schwartzberg
- Francis P. Arena
- Bryan J. Bienvenu
- Luis H. Camacho
- Luis T. Campos
- J. Paul Waymack
- Mary Ann Tagliaferri
- Michael M. Chen
- Dapeng Li
References
- Cancer statistics, 2016
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer
- Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer.
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010
- Coix seed extract, A commonly used treatment for cancer in china, inhibits NFκB and protein kinase C signaling